| 爱沙尼亚医药公司寻求投资合作 |
|
| 2009-04-15 15:53 文章来源：中国驻爱沙尼亚使馆经商处 | | 文章类型：原创 内容分类：供求 |
爱医药公司Vitale-XD Ltd希望向中国医药企业出售股份，建立合资企业，共同开发爱沙尼亚、欧盟及独联体国家市场。
爱公司名称：Vitale-XD Ltd
电话：00372-6546922
传真：00372-6546921
vitale@infonet.ee
www.vitale.ee
附：Vitale-XD Ltd公司情况
The manufacturing of effervescent tablets
Our objectives
The effervescent tablets manufacturing is a modern project, which has been started in Estonia for the first time. The manufacturing is designed from the cycle beginning and is based on Hoffmann-La Roche’s formulas and technology.
Rooms and equipment available
The project started off from manufacturing multivitamins in the beginning of 2001. The rooms were rented from a Technopol for the drug manufacturing purpose. These rooms were then reconstructed to suit the required manufacturing conditions for a pharmaceutical industry.
For tableting we use the new FETTE 1200PC tabletpress, which has maximum operation speed of 130000 tablets/hour.
Licenses and marketing authorizations for drugs
We are licensed by the Estonian State Agency of Medicines (the activity license valid until October 01, 2013).
The manufacturing has been authorized with the following national legislation:
Medicinal Products Act, enforced on April 1, 1996, Art 6 section 1. The manufacturing has been inspected by the supervisory authority-State Agency of Medicines of Estonia and has GMP Certificate.
During the project existing time about 0,7 million EUR has been invested into GMP implementation.
The following products are being produced now:
1. Pexvital, Apovit (multivitamins),
2. Asprovit C (400 mg acetylsalicylic acid and 300 mg ascorbic acid containing drug),
3. Asprovit (500 mg acetylsalicylic acid containing drug)
4. Paracetamol DM (300 mg paracetamol and 7,5 mg dextromethorphan hydrobromide containing drug),
5. Panivit (500 mg paracetamol and 200 mg ascorbic acid),
6. Aspavit (330 mg acetylsalicylic acid and 200 mg ascorbic acid),
7. Vitamin C (50 mg, 250 mg, 500 mg, 1000 mg)
8. 10 formulations of vitamins+minerals, UK sub-contracting
9. SportActive, vitamins+minerals, Sweden, USA
10. Bath tablets, Germany sub-contracting
11. Aspinat (500 mg acetylsalicylic acid), Aspinat C (400 mg acetylsalicylic acid and 240 mg ascorbic acid containing drug), Aspinat Alko (324 mg acetylsalicylic acid and 80 mg succinic acid), Aspinat Complex (500 mg acetylsalicylic acid, 15 mg phenylephrine, 5 mg pheniramine maleate), Russia sub-contracting., 1,5 mln pakendit
12. Antigrippin-ORVI (500 mg paracetamol, 100 mg ascorbic acid, 10 mg phenylephrine hydrochloride)-ValentaPharm, Russia, 1,5 mln pakendit, 2009.a.
13. ACC-acetylcysteine, 200 mg, 600 mg, ZAO Vertex, St.-Peterburg, 600 tuh.pakendit
14. BioMax, vitamins+minerals, ValentaPharm, Russia, 1 mln pakendit 2009. a.
All of the above listed medicines have marketing authorisations in Estonia, Russia, Republic of Belarus, Ukraine, Georgia, Kazakhstan and Azerbaijan.
Personnel
The staff members have high qualifications, which is required for a pharmaceutical industry. The top managers are experienced to work in the domestic market and in the markets of other countries. The introductive, basic and ongoing training programs are required by the GMP, which are being run for each personnel member.
The future products
We are searching for a strategic business partner for the development of new products and new markets.
Materials in use and suppliers
All the raw materials, which are in use by us are pharmaceutical grade chemicals. The approved suppliers of the drug ingredients meet the GMP requirements and marketing authorisations. For example, the active substances for multivitamins are supplied as a ready premix by DSM Nutritional. Here are some names of other suppliers of active substances: Dolder AG and Plantaria AG, Switzerland, Rhodia, France, Algol Chemicals Finland, Suzhou Fine Chemicals CO, Shijiazhuang Pharma, Zhejiang Kangle Pharmaceutical CO, etc.
Each ingredient batch is tested before releasing into production in our quality control laboratory.
Additonal information
This project is unique due to the fact that all drugs are not subjects of medicinal prescription and are used by a wide consumer groups.
There is a lot of potential in our company and this potential can be seen in the development and production of new products. In order to get income from the production of new products, we are seeking for a strategic business partner, who will deal with the marketing and selling of these products.
Best regards
Raissa Shushuyeva
Chairman of the Board
|
|
经贸新闻
